264 related articles for article (PubMed ID: 21666484)
1. Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers.
Felix AS; Stone RA; Bowser R; Chivukula M; Edwards RP; Weissfeld JL; Linkov F
Int J Gynecol Cancer; 2011 Jul; 21(5):877-84. PubMed ID: 21666484
[TBL] [Abstract][Full Text] [Related]
2. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
[TBL] [Abstract][Full Text] [Related]
3. Comparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital.
Prueksaritanond N; Chantape W
J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S75-83. PubMed ID: 27266220
[TBL] [Abstract][Full Text] [Related]
4. Malignant mixed müllerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival.
George E; Lillemoe TJ; Twiggs LB; Perrone T
Int J Gynecol Pathol; 1995 Jan; 14(1):39-44. PubMed ID: 7883424
[TBL] [Abstract][Full Text] [Related]
5. The comparison of clinicopathological characteristics in primary malignant mixed műllerian tumour with epithelial endometrial carcinoma.
Tong SY; Lee JM; Choi YJ; Lee JK; Kim JW; Cho CH; Kim SM; Park SY; Park CY; Kim KT
Aust N Z J Obstet Gynaecol; 2012 Feb; 52(1):44-8. PubMed ID: 22188343
[TBL] [Abstract][Full Text] [Related]
6. Survival Differences Among Uterine Papillary Serous, Clear Cell and Grade 3 Endometrioid Adenocarcinoma Endometrial Cancers: A National Cancer Database Analysis.
McGunigal M; Liu J; Kalir T; Chadha M; Gupta V
Int J Gynecol Cancer; 2017 Jan; 27(1):85-92. PubMed ID: 27759595
[TBL] [Abstract][Full Text] [Related]
7. Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study.
Greggi S; Mangili G; Scaffa C; Scala F; Losito S; Iodice F; Pisano C; Montoli S; Viganò R; Pirozzi G; Giannarelli D
Int J Gynecol Cancer; 2011 May; 21(4):661-7. PubMed ID: 21412164
[TBL] [Abstract][Full Text] [Related]
8. Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma.
Vaidya AP; Horowitz NS; Oliva E; Halpern EF; Duska LR
Gynecol Oncol; 2006 Nov; 103(2):684-7. PubMed ID: 16797683
[TBL] [Abstract][Full Text] [Related]
9. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 1999 Sep; 74(3):385-94. PubMed ID: 10479498
[TBL] [Abstract][Full Text] [Related]
10. A clinical and biological comparison between malignant mixed müllerian tumors and grade 3 endometrioid endometrial carcinomas.
Bland AE; Stone R; Heuser C; Shu J; Jazaeri A; Shutter J; Atkins K; Rice L
Int J Gynecol Cancer; 2009 Feb; 19(2):261-5. PubMed ID: 19396006
[TBL] [Abstract][Full Text] [Related]
11. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.
Benedetti Panici P; Basile S; Maneschi F; Alberto Lissoni A; Signorelli M; Scambia G; Angioli R; Tateo S; Mangili G; Katsaros D; Garozzo G; Campagnutta E; Donadello N; Greggi S; Melpignano M; Raspagliesi F; Ragni N; Cormio G; Grassi R; Franchi M; Giannarelli D; Fossati R; Torri V; Amoroso M; Crocè C; Mangioni C
J Natl Cancer Inst; 2008 Dec; 100(23):1707-16. PubMed ID: 19033573
[TBL] [Abstract][Full Text] [Related]
12. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
[TBL] [Abstract][Full Text] [Related]
13. The Growing Burden of Endometrial Cancer: A Major Racial Disparity Affecting Black Women.
Cote ML; Ruterbusch JJ; Olson SH; Lu K; Ali-Fehmi R
Cancer Epidemiol Biomarkers Prev; 2015 Sep; 24(9):1407-15. PubMed ID: 26290568
[TBL] [Abstract][Full Text] [Related]
14. Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers.
Pothuri B; Ramondetta L; Eifel P; Deavers MT; Wilton A; Alektiar K; Barakat R; Soslow RA
Gynecol Oncol; 2006 Dec; 103(3):948-51. PubMed ID: 16870239
[TBL] [Abstract][Full Text] [Related]
15. Does the FIGO 2009 endometrial cancer staging system more accurately correlate with clinical outcome in different histologies? Revised staging, endometrial cancer, histology.
Page BR; Pappas L; Cooke EW; Gaffney DK
Int J Gynecol Cancer; 2012 May; 22(4):593-8. PubMed ID: 22343970
[TBL] [Abstract][Full Text] [Related]
16. The Prognosis of Stage IA Mixed Endometrial Carcinoma.
Li W; Li L; Wu M; Lang J; Bi Y
Am J Clin Pathol; 2019 Oct; 152(5):616-624. PubMed ID: 31318970
[TBL] [Abstract][Full Text] [Related]
17. Clear cell and papillary serous endometrial carcinomas: survival in a series of 128 cases.
Scarfone G; Secomandi R; Parazzini F; Viganò R; Mangili G; Frigerio L; Villa A; Tateo S; Ricci E; Bolis G
Arch Gynecol Obstet; 2013 Feb; 287(2):351-6. PubMed ID: 23100038
[TBL] [Abstract][Full Text] [Related]
18. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
19. How do different histologic components of mixed endometrial carcinomas affect prognosis? Does it really matter?
Thomakos N; Dimopoulou S; Sotiropoulou M; Machairiotis N; Pandraklakis A; Haidopoulos D; Liontos M; Bamias A; Rodolakis A
Horm Mol Biol Clin Investig; 2020 Dec; 42(1):105-111. PubMed ID: 33781006
[TBL] [Abstract][Full Text] [Related]
20. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women.
Matthews RP; Hutchinson-Colas J; Maiman M; Fruchter RG; Gates EJ; Gibbon D; Remy JC; Sedlis A
Gynecol Oncol; 1997 May; 65(2):206-12. PubMed ID: 9159326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
